Hydrochlorothiazide / triamterene Pregnancy and Breastfeeding Warnings

Brand names: Dyazide, Maxzide, Maxzide-25

Medically reviewed by Drugs.com. Last updated on Jun 12, 2024.

Hydrochlorothiazide / triamterene Pregnancy Warnings

Safety has not been established during pregnancy.

AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned

Risk summary: No data are available on the use of this drug in pregnant women to inform a drug-related risk.

Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Hydrochlorothiazide / triamterene Breastfeeding Warnings

UK: Use should be avoided.
AU and US: This drug should not be used unless there are no safer alternatives.

Excreted into human milk: Yes (hydrochlorothiazide); Unknown (triamterene)
Excreted into animal milk: Yes (triamterene)

Comments: Some authorities consider use of this drug acceptable during lactation if required by the mother and assuming a hydrochlorothiazide dose of 50 mg/day or less.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer